IGF2BP3 and non-small cell lung carcinoma: Notably, its expression in non-small-cell lung cancer (NSCLC) has also been described, and further functional studies have demonstrated that silencing IGF2BP3 via shRNA (shIGF2BP3) significantly reduces cell growth and colony formation in the A549 cell line, providing preliminary evidence for its role in lung cancer progression [13,14].